Free Newsletter
Editor's Corner

![]()
No guarantees against fraud
You have to sympathize with the editors at Science magazine (see the story below). They were the unwitting victims of research fraud, agreeing to publish the scandalously fictionalized cloning work of Hwang Woo-Suk. At the time, of course, it was the stuff of worldwide headlines. But it proved to be too good to be true--for now. Ultimately, when a world-renowned scientist opts to make up study results, there really isn't a fail-safe fact-checking process that any journal can implement without completely disrupting their production schedule.
This wasn't the work of some obscure scientist with a suspicious background. The peer-review process was handled appropriately and the magazine has done an outstanding overall job in screening what it publishes. The fallout from this incident has terminated the scientist's credibility. That's appropriate. Let's encourage all the journals to take a more skeptical approach when new findings are particularly sensational. But in an age that sees a lot of jaw-dropping science every week, we also need to understand that occasionally some fraudulent studies will get through. The harsh retribution faced by rogue scientists is the most effective deterrent against future fraud. - John Carroll
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




